Monoclonal Protein on Serum Protein Electrophoresis (M Component)
Monoclonal gammopathy of unknown significance (MGUS)
Low concentration of monoclonal immunoglobulins (LCMI)
Heavy chain disease
Suggested Additional Lab Testing
For multiple myeloma:
In addition to SPEP followed by immunofixation, quantitative serum immunoglobulin should be performed, because the M component must be greater than3 g/dL in the serum.
Bone marrow aspirate may be useful to show that at least 10% of the nucleated blood cells are plasma cells.
Bone marrow biopsy may be useful to show aggregates of plasma cells in focal or diffuse patterns.
CBC often reveals a normochromic normocytic anemia.
Peripheral blood smear often shows RBCs in a stacked or rouleaux formation.
For Waldenstrom macroglobulinemia:
Immunofixation to identify the M component as an IgM immunoglobulin with a quantitative IgM level greater than 3 g/dL
Serum viscosity is usually increased.
Peripheral blood smear often shows RBC aggregates in a rouleaux formation.
For heavy chain disease:
Immunofixation reveals the heavy chain as alpha, gamma, or mu.
Bone marrow examination may be informative.
Quantitative determination of the serum M component to demonstrate that an IgG or IgM monoclonal protein is less than 3.0 g/dL or an IgA monoclonal protein is less than 2.0 g/dL, or that a Bence-Jones protein is less than or equal to 1.0 g in a 24-hour urine specimen
Copyright © 2017, 2013 Decision Support in Medicine, LLC. All rights reserved.
No sponsor or advertiser has participated in, approved or paid for the content provided by Decision Support in Medicine LLC. The Licensed Content is the property of and copyrighted by DSM.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Considerations for Relapsed Myeloma Should Match Patient, Disease, and Therapy
- Triclosan and Cancer Risk: Is There a Link?
- Drugs Approved Under the Breakthrough Therapy Pathway Lack Basic Features of High-Quality Trials
- Combined Modality Therapy May Be More Effective Than Radiotherapy Alone in Follicular Lymphoma
- Chemotherapy May Improve Survival Outcomes in High-Risk Soft-Tissue Sarcoma